Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:CIR
- CUSIP: N/A
- Web: www.circassia.com/
- Market Cap: £256.16 million
- Outstanding Shares: 284,622,000
- 50 Day Moving Avg: GBX 89.17
- 200 Day Moving Avg: GBX 92.03
- 52 Week Range: GBX 78.45 - GBX 114
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £23.1 million
- Price / Sales: 11.09
- Book Value: GBX 0.99 per share
- Price / Book: 0.91
- EBIDTA: ($66,300,000.00)
- Net Margins: -296.67%
- Return on Equity: -23.45%
- Return on Assets: -20.22%
- Average Volume: 97,858 shs.
Frequently Asked Questions for Circassia Pharmaceuticals PLC (LON:CIR)
What is Circassia Pharmaceuticals PLC's stock symbol?
Circassia Pharmaceuticals PLC trades on the London Stock Exchange (LON) under the ticker symbol "CIR."
When will Circassia Pharmaceuticals PLC make its next earnings announcement?
Where is Circassia Pharmaceuticals PLC's stock going? Where will Circassia Pharmaceuticals PLC's stock price be in 2017?
4 brokers have issued 1 year price objectives for Circassia Pharmaceuticals PLC's stock. Their forecasts range from GBX 120 to GBX 174. On average, they expect Circassia Pharmaceuticals PLC's share price to reach GBX 143.50 in the next year. View Analyst Ratings for Circassia Pharmaceuticals PLC.
Who are some of Circassia Pharmaceuticals PLC's key competitors?
Some companies that are related to Circassia Pharmaceuticals PLC include Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI), G1 THERAPEUTICS (GTHX), Jounce Therapeutics (JNCE), Adaptimmune Therapeutics PLC (ADAP), AnaptysBio (ANAB), NantKwest (NK), Atara Biotherapeutics (ATRA), AVEO Pharmaceuticals (AVEO), Karyopharm Therapeutics (KPTI), Progenics Pharmaceuticals (PGNX), Mersana Therpts (MRSN), BioCryst Pharmaceuticals (BCRX), Ra Pharmctl (RARX), GlycoMimetics (GLYC), BioSpecifics Technologies Corp (BSTC), Geron Corporation (GERN) and Edge Therapeutics (EDGE).
Who are Circassia Pharmaceuticals PLC's key executives?
Circassia Pharmaceuticals PLC's management team includes the folowing people:
- Francesco Granata M.D., Non-Executive Chairman of the Board
- Steven Harris, Chief Executive Officer, Executive Director
- Julien Cotta, Chief Financial Officer, Executive Director, Company Secretary
- Rod Hafner, Director and Senior Vice President Research & Development, Executive Director
- Russell Cummings, Non-Executive Director
- Jean-Jacques Garaud M.D., Senior Independent Non-Executive Director
- Marvin S. Samson, Independent Non-Executive Director
- Lota S. Zoth CPA, Independent Non-Executive Director
How do I buy Circassia Pharmaceuticals PLC stock?
Shares of Circassia Pharmaceuticals PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Circassia Pharmaceuticals PLC's stock price today?
MarketBeat Community Rating for Circassia Pharmaceuticals PLC (LON CIR)MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Circassia Pharmaceuticals PLC stock can currently be purchased for approximately GBX 90.
Consensus Ratings for Circassia Pharmaceuticals PLC (LON:CIR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 143.50|
Analysts' Ratings History for Circassia Pharmaceuticals PLC (LON:CIR)
(Data available from 8/22/2015 forward)
|5/26/2017||Numis Securities Ltd||Reiterated Rating||Buy||GBX 174|
|5/23/2017||J P Morgan Chase & Co||Reiterated Rating||Neutral||GBX 120|
|4/26/2017||Peel Hunt||Downgrade||Hold||GBX 150 -> GBX 130|
|4/25/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 150|
|6/21/2016||Barclays PLC||Initiated Coverage||Overweight||GBX 410 -> GBX 170|
|6/21/2016||Royal Bank Of Canada||Downgrade||Sector Performer||GBX 430 -> GBX 105|
Earnings History for Circassia Pharmaceuticals PLC (LON:CIR)Earnings History by Quarter for Circassia Pharmaceuticals PLC (LON CIR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Circassia Pharmaceuticals PLC (LON:CIR)
Current Year EPS Consensus Estimate: $-35.39 EPS
Dividend History for Circassia Pharmaceuticals PLC (LON:CIR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Circassia Pharmaceuticals PLC (LON:CIR)Insider Trades by Quarter for Circassia Pharmaceuticals PLC (LON:CIR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/2/2017||Jean-Jacques Garaud||Insider||Sell||77,500||GBX 89||£68,975|
Headline Trends for Circassia Pharmaceuticals PLC (LON:CIR)
Latest Headlines for Circassia Pharmaceuticals PLC (LON:CIR)
Circassia Pharmaceuticals PLC (CIR) Chart for Tuesday, August, 22, 2017